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ABSTRACT 
Coronavirus disease 2019 (COVID-19) has become a world pandemic since early 2020.
Currently, there is no established treatment to combat this potentially fatal disease. 
Convalescent plasma (CP) therapy has a strong scientific basis and historical perspective 
to treat previous viral infections such as Ebola, Middle East respiratory syndrome (MERS) 
and severe acute respiratory syndrome (SARS). The aim of this review was to evaluate 
the efficacy and safety of convalescent plasma CP therapy in patients with COVID-19.
We searched for every available study from major databases (CENTRAL, MEDLINE via 
Ovid, EMBASE) through 20th April 2020. We independently screened, extracted, assessed 
the risk of bias, analyzed the data using SPSS version 26, and narratively summarized 
the data. For the outcomes, we wanted to evaluate the changes of clinical parameters, 
radiological appearance, pulmonary function, the titer of neutralizing antibody, 
viral load, the disappearance of severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2) RNA, and adverse events.We found five case series from our literature 
searching. The overall methodological quality of the case series was moderate. We 
included 27 patients, and all patients received CP transfusion. All patients experienced 
improvement of clinical symptoms and pulmonary lesions after receiving 200 to 2400 
mL (median 200 mL) of CP transfusion. All patients in reported studies had negative 
results of reverse transcriptase-polymerase chain reaction(RT-PCR) after 1 to 26 days of 
transfusion (median 3 days). There was one non-life threatening adverse event reported 
after CP transfusion (facial red spot). In conclusion, CP therapy in COVID-19 patients 
showed promising results as it improved clinical symptoms and parameters, and it is 
well-tolerated based on our included studies. However, further expanded clinical trials 
with better designs are still required to evaluate the efficacy of this treatment although 
suchidea will be quite challenging to be conducted in the era of an epidemic.
ABSTRAK
Coronavirus disease 2019 (COVID-19) menjadi pandemik dunia sejak awal tahun 2020.
Hingga saat ini belum ada terapi yang efektif untuk penyakit yang berpotensi mematikan 
ini. Terapi plasma konvalesen (PK) atau plasma sembuh mempunyai landasan ilmiah 
yang kuat dan sejarah yang cukup panjang sebagai terapi infeksi virus seperti pada 
wabah Ebola, Middle East respiratory syndrome (MERS) dan severe acute respiratory 
syndrome (SARS). Tinjauan pustaka ini bertujuan mengevaluasi kemampuan dan 
keamanan terapi PK pada pasien COVID-19.Tinjauan pustaka secara cepat dilakukan 
dengan mencari literatur dari database penelitian besar, seperti CENTRAL, MEDLINE, 
dan EMBASE sampai tanggal 20 April 2020. Kami melakukan penyaringan abstrak, 
ekstraksi data, menganalisa kualitas penelitian, dan secara naratif menjelaskan data 
yang ada. Kami mengumpulkan data disesuaikan keluaran yang telah kami rumuskan 
sebelumnya, yaitu perubahan parameter klinis, perubahan gambaran radiologi paru-
paru, perubahan fungsi paru-paru, titer neutralizing antibody, viral load, dan efek 
samping setelah transfusi PK. Kami memasukkan 5 studi case-series pada tinjauan 
ini, dengan total 27 pasien. Enam belas dari 27 pasien adalah pasien dengan kategori 
klinis berat. Semua pasien mendapatkan terapi PK dengan volume bervariasi dari 200 
sampai 2400 mL (median 200 mL). Semua pasien mengalami perbaikan dari segi klinis, 
perbaikan gambaran radiologis, dan hasil negatif reverse transcriptase-polymerase chain 
reaction (RT-PCR) setelah 1 sampai 26 hari transfusi (median 3 hari). Dapat disimpulkan, 
terapi PK menunjukkan hasil yang menjanjikan dalam memperbaiki keadaan klinis, 
dan cukup aman untuk pasien COVID-19 berdasarkan berbagai penelitian. Namun 
demikian masih diperlukan penelitian yang melibatkan lebih banyak pasien dan 
dengan rancangan penelitian yang lebih baik untuk menilai efektifitas terapi PK yang 
sesungguhnya, meskipun hal ini menjadi hal yang sangat menantang dalam situasi 
pandemik.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) 
is a disease that emerged from Wuhan 
Province in China in December 2019.1 
This disease became a world pandemic 
in early 2020 and already infected more 
than 2.4 million people in the world on 
the 20th of April 2020.2 It is caused by 
the severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2), an RNA 
virus, and belongs as a species from 
betacoronavirus genus. This virus is the 
seventh coronavirus that infects human.3
World Health Organization (WHO) 
and other clinical institutions have 
not yet established any definitive 
treatment for handling this disease, 
because specific treatment is still under 
research.4 Antivirals, such as favipiravir, 
oseltamivir, are used, however, patients’ 
responses while receiving this medication 
are still diverse. Furthermore, the 
mortality rate of COVID-19 remains 
around 5.21% from all cases.2,5
Convalescent plasma (CP) therapy 
is suggested to be used as an adjunctive 
treatment for this disease.6 This 
approach was used in Ebola, Middle 
East respiratory syndrome (MERS) and 
severe acute respiratory coronavirus 
(SARS-CoV) infection, and several studies 
showed promising results. Convalescent 
plasma therapy works to decrease 
the viral load, cytokine response, and 
mortality rate. In addition, CP therapy 
also works by transferring antibody of a 
certain infectious agent from survivors 
to patients who are infected with the 
same agent of disease. This form of 
passive immunity helps the patient to 
fight the disease from getting worse 
immediately.7 The CP had been used in 
a small population of severe COVID-19 
patients, and the results were appeared 
promising from this population.8 We 
conducted a rapid review to evaluate 
the efficacy and safety of CP therapy in 
patients with COVID-19.
MATERIALS AND METHODS 
Type of participants
We included all patients who were 
confirmed with COVID-19 using throat 
swab SARS-CoV-2 reverse transcriptase-
polymerase chain reaction (RT-PCR) 
in all ages, all clinical stages, and all 
sexes. We defined the clinical stages 
or severity of disease based on the 
WHOClinical Classification of COVID-19.9 
Asymptomatic patients were patients 
without any clinical symptoms of 
COVID-19. Patients with mild disease 
were patients without any specific 
symptoms, such as fever, weakness, 
cough, and malaise. Patients with 
moderate disease were those who had 
signs and symptoms of pneumonia, 
but did not require supplemental 
oxygen. Patients with severe disease 
were patients with clinical signs and 
symptoms of pneumonia, and had one 
form these conditions: respiratory rate ≥ 
30 times per minute, severe respiratory 
distress, oxygen saturation (SpO2) < 93% 
in room air, or PaO2/ FiO2 ratio <300. We 
defined critically ill patients as those who 
experienced acute respiratory distress 
syndrome (ARDS), septic shock, and/ or 
multiple organ failure. We also included 
those patients who were already treated 
with other regimens, such as antivirals, 
interferon-alpha (INFα), and other 
supportive treatments before receiving 
CP therapy.
Type of interventions
Patients received CP containing 
the SARS-CoV-2 antibody (IgG). The CP 
was drawn from individuals who had 
recovered from COVID-19, could donate 
blood, had no symptoms for 14 days, 
and had showed negative results on 
COVID-19 tests.
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Treatment outcomes
Our primary outcomes were to 
evaluate the clinical responses in patients 
who were treated with CP, such as 
changes of clinical parameters, changes 
of radiological appearance, changes 
of PaO2 / FiO2, the titer of neutralizing 
antibody, viral load, the disappearance 
of SARS-COV-2 RNA, and adverse events 
if available. Our secondary outcome 
was to evaluate whether there was any 
variation of clinical response based on 
the severity of COVID-19 disease. 
Type of studies
We wanted to include any types 
of publications regarding our clinical 
questions, except systematic reviews. 
We also excluded animal studies.
Search strategy and literature review
Two authors (DPP and MS) 
independently conducted literature 
searching through major databases, 
such as MEDLINE via Ovid, EMBASE, and 
Cochrane Controlled Register of Trials 
(CENTRAL) until 20th April 2020. We did 
not cover grey literature and limited the 
studies with English language only. We 
used keywords related to our clinical 
questions (COVID-19 and convalescent 
plasma therapy). Full search strategies 
are available in APPENDIX 1.
Selection of  studies and data 
extraction
The process of searching and 
screening of abstracts of the relevant 
studies were done independently by DDP 
and MS. We extracted the data according 
to our outcomes into standardized tables. 
Risk of bias assessment
We evaluated the risk of bias of our 
included studies using Cochrane risk-
of-bias tool for controlled trials. For 
observational studies (cohort, cross-
sectional or case-control studies), we 
used Strengthening the Reporting of 
Observational studies in Epidemiology 
(STROBE) checklist. For case reports or 
case-series, we assessed the quality of 
studies using a tool by Joanna Briggs 
Institute.10 
Data synthesis
We narratively synthesized the data 
and collected the data in tabular fashion. 
We also summarized the patient’s 
baseline characteristics and calculated 
the median of age, days of convalescent 
therapy initiation, days of negative RT-
PCR results after CP administration, 
and other outcomes measured using 
SPSS version 26. For the uncontrolled 
studies and one-arm studies, we did not 
conduct meta-analysis since it would be 
inappropriate as there are no controlled 
arm as the comparisons. Therefore, 
all available data that we already had 
extracted were discussed narratively. 
The authors discussed the details of all 
the taken steps and analysis. The authors 
also discussed all the different opinions 
raised by the analysis result thoroughly 
before wrapping up the final opinion in 
the manuscript.
RESULTS 
From the literature searching, in the 
beginning, we found 56 studies related 
to our keywords. After we eliminated 
the duplicates, we found 40 studies. We 
screened the abstracts and only included 
trials, observational studies, or case 
reports, and we found six studies, and all 
of the studies were case series. However, 
one study was lack of information 
regarding the patients’ characteristics, 
therefore we excluded the study from 
our review.11 Overall, the quality of the 
case series was of moderate quality. 
All of the studies defined the patients' 
characteristics, intervention given, 
length of follow-ups, and outcomes 
measured.
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FIGURE 1. Study flow diagram.
TABLE 1.List of included studies
Authors
Publication 
type
No. of 
patients
Country
Patients 
characteristics
Intervention
Ahn,et al.12 Case Series 2 Korea Two elderly 
patients (71-year-
old man and 
a 67-year-old 
woman) with 
severe COVID-19
500 mL of plasma from 
recovered COVID-19 
patients with Optical 
density ratio to IgG 0.586 
and 0.532 divided into two 
doses.
Duan, et al.13 Case Series 10 China 10 severe COVID-19 
patients confirmed 
with rtPCR, age 
34-78 years old 
(median 52.5 
years old), with 
varied comorbid 
conditions.
One dose of 200 mL of 
convalescent plasma 
(CP) from recently 
recovered donors with 
the neutralizing antibody 
titers above 1:640 
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Shen, et al.8 Case Series 5 China 5 critically ill 
patients (severe) 
confirmed with 
COVID-19 by rtPCR 
and ARDS, age 
range 36-65 years
Patients received 
transfusion with 
convalescent plasma 
with a SARS-CoV-2– (IgG) 
binding titer greater than 
1:1000  and neutralization 
titer greater than 40) 
Ye, et al.14 Case Series 6 China 6 COVID-19 
patients confirmed 
by using throat 
swab SARS-CoV-2 
real-time PCR, age 
28-75 years old
Patients received at 
least one cycle of ABO-
compatible convalescent 
plasma transfusion (200ml 
for each cycle, varied 
from 1-3 cyclers) and 
administered over 30 
minutes.
Zhang, 
et al.15
Case Series 4 China 4 critically ill 
COVID 19 patients, 
age 31-73 years old. 
Varied dosage of plasma 
convalescent was used 
(200 to 2400 mL divided 
into 1 to 8 cycles).
TABLE 2. Patients characteristics from 5 case series
Characteristics n (%) Median (IQR)
Age (years) 57 (20)
Sex
•	 Male 15 (56)
•	 Female 12 (44)
Country
•	 China 25 (93)
•	 Korea 2 (7)
Severity of disease
•	 Asymptomatic 1 (4)
•	 Mild 1 (4)
•	 Severe 16 (59)
•	 Critically III 9 (33)
Comorbid
•	 No Comorbid 15 (56)
•	 Hypertension 7 (26)
•	 Others 5 (18)
Total dosage of CP transfusion (mL) 200 (200)
Initiation of CPtherapy after hospital admission (days) 11 (10)
Negative result of COVID-19 RNA after transfusion (days) 3 (8)
In total, there were 27 patients 
included in our review. The majority of 
the case series were reported in China, 
and only one study was reported from 
Korea. The patients' age ranged from 
28 to 78 years old with a median age of 
the patients was 57 years old. Sixteen 
patients from the total 27 patients had 
severe disease, followed by nine patients 
with critically ill condition, and the rest 
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two patients were one asymptomatic and 
one with mild to moderate condition. 
The initiation of CP therapy varied 
from 3 days to 28 days after hospital 
admission, with a median of 11 days. The 
dose of CP was varied from 200 to 2400 
mL and the administration was divided 
into one up to nine cycles. Hypertension 
was the most common comorbid in 
our included patients, while other 
comorbid conditions were heart disease, 
pulmonary disease, end-stage renal 
disease, Sjögren disease, and pregnancy. 
All of the patients had already received 
antivirals therapy (lopinavir/ritonavir, 
arbidol, favipiravir, darunavir) and 14 
(52%) patients received corticosteroids 
therapy prior to CP transfusion. Other 
treatments given to the patients were 
antibiotics, antifungals, and Interferon-α 
therapy.
Clinical symptoms
All studies reported the 
improvement of clinical symptoms 
after the administration of CP therapy, 
especially symptoms of fever, dyspnea, 
and cough.8,12-15 Examples of clinical 
symptoms improvement can be seen 
from the number of patients who were 
successfully extubated (10 out of 13 
patients). The study by Shen et al showed 
four out of five patients had their fever 
relieved 12 days after administration 
of CP therapy and had improvement of 
SOFA score.8
Improvement of chest radiology
All of the studies reported marked 
resolution of radiological findings. The 
study by Ahn et al showed two patients 
had marked improvement in bilateral 
infiltration.12 These improvements 
occured in four to six days after the 
initiation of CP therapy, respectively. 
The study by Duan et al.13 also showed 
different degrees of chest CT scan 
improvement after convalescent 
plasma transfusion, and two patients 
showed significant pulmonary lesions 
improvement in three to five days after 
transfusion. 
Pulmonary function
Only two studies conducted by 
Ahn et al.8 and Shen et al.12 showed the 
changes in pulmonary function after CP 
transfusion. The mean of PaO2/FiO2 ratio 
increased after the administration of CP 
transfusion.8,12
TABLE 3. Changes of pulmonary function in sevenpatients
Out put Before CP transfusion
After CP transfusion
Mean of pulmonary 
function (PaO2/FiO2 ratio)a 173.1 (70.9) 308.6 (43.8)
a In seven patients
Day of extubation
In total, there were 13 patients 
received mechanical ventilation, and 
10 patients were successfully weaned 
and extubated.8,12-15 Previous studies 
reported days of extubation after the 
patients were administered with the CP 
transfusion.8,12,15 The day of extubation 
after CP therapy varied from two days to 
39 days, with a median of 12 days. The 
study by Duan et al.13 did not report the 
day of the extubation of the intubated 
patients, but the study reported the 
condition after the therapy. This study 
showed one out of three patients was 
still intubated. Shen et al.8 reported that 
two patients were still intubated after 
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the administration of the CP therapy. 
However, the pulmonary function 
of these patients had improved and 
one patient was removed from an 
extracorporeal membrane oxygenation 
(ECMO) ventilation and was continued 
intubated. Whereas, Zhang et al.15 
reported that one patient was still 
intubated and transferred into an 
unfenced ICU due to multiple organ 
failure.15
Titer of viral neutralizing antibody 
Viral neutralizing antibody 
assessment is important parameter that 
indicate the amount of antibody that is 
capable of neutralizing the viral. There 
was generally increased value of this 
parameter almost in all reported subjects 
as seen in TABLE 4.
TABLE 4. Change of viral neutralizing antibody 
before and after 1 to 7 days of CP 
transfusion in 15 patients.8,13
P a t i e n t 
No.
Before CP 
Transfusion
After CP 
Transfusion
1a 1/160 1/640
2a Negative Negative
3a 1/320 1/640
4a 1/160 1/640
5a 1/640 1/640
6a 1/640 1/640
7a 1/320 1/640
8a 1/640 1/640
9a 1/160 1/640
10a 1/640 1/640
11b 1/160 1/320
12b 1/40 1/160
13b 1/40 1/160
14b 1/80 1/240
15b 1/80 1/480
a Patients from Duan et al.13 study; bPatients from 
Shen et al.8 study
From the study by Duan et al.13 nine 
patients had their neutralizing antibody 
detected before transfusion, and nine 
patients had neutralizing antibody 
titers of 1:640 after one to five days after 
transfusion. The study from Shen et al.8 
showed increased neutralizing antibody 
titers in all patients after seven days of 
transfusion.
Assessment of viral load
Assessment of qRT-PCR for SARS-
CoV-2 from nasopharyngeal swabs 
indicated by Ct value indicates the viral 
load. Each RT-PCRassay provided a Ct 
value, which is the number of cycles 
required for the fluorescent signal to 
cross the threshold for a positive test: 
a higher Ct value is correlated with a 
lower viral load. The specimens were 
considered positive if the Ct value was 
37.0 or lower and negative if the results 
were undetermined. Specimens with a 
Ct value higher than 37 were repeated. 
The specimen was considered positive 
if the repeated results were the same as 
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the initial result and between 37 and 40. 
If the repeated Ct was undetectable, the 
specimen was considered negative.
The viral load became negative in 
most of the cases after CP transfusion. 
The results of negative qRT-PCR were 
achieved between one day to 26 days 
after transfusion (median 3 days after CP 
transfusion) based on all included studies 
(Table 2).8,12-15 Table 5 summarized the 
viral load change in 17 patients based on 
the three studies that reported Ct value 
before and after transfusion.8,12,13 From 
this table, the negative qRT-PCR achieved 
after CP transfusion was similar, one to 26 
days (median 2 days) after transfusion.
TABLE 5. Changes of SARS-CoV-2 RNA load in 17 observed 
patients before and after convalescent plasma 
transfusion
Patients 
No.
Ct value before CP 
transfusion
Ct value after CP 
transfusion
Days after 
transfusion
1a 25.0 Negative 26
2a 20.5 Negative 20
3b 37.3 Negative 1
4b 35.1 Negative 2
5b 38.1 Negative 1
6b 37.7 Negative 1
7b Negative Negative 2
8b Negative Negative 2
9b 34.6 Negative 2
10b 35.5 Negative 2
11b Negative Negative 2
12b 38.2 Negative 5
13c 28.5 Negative 12
14c 22.0 Negative 12
15c 33.0 Negative 3
16c 26.6 Negative 3
17c 35.9 Negative 1
aStudy by Ahn et al.12; bStudy by Duan et al.13; cStudy by Shen et 
al.8; Ct value: cycle threshold value
Adverse events
There was only one mild side effect 
reported in the included studies. Duan et 
al showed one patient having a mild side 
effect from experiencing facial red spot, 
not a life-threatening condition.13
Mortality
All studies did not report any 
mortality after the transfusion. 
Therapy response based on clinical 
severity
Only one asymptomatic and one 
patient with mild category of disease 
were included in our review, and they had 
negative RT-PCR results after transfusion. 
All 16 severe patients also had negative 
RT-PCR results and improvement in 
clinical parameters after transfusion. 
There were nine critically ill patients, 
three patients were still intubated until 
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the study end-point observation.8,15 One 
critical ill patient from Zhang et al.15 
study received the highest total dose 
of CP therapy transfusion (2400 mL 
divided into nine cycles), and the patient 
remained intubated due to multiple 
organ failure.15 The rest of six critically 
ill patients improved clinically and 
showed negative qRT-PCR result after CP 
transfusion. 
DISCUSSION
Our review only included case series 
as until the end of our literature searching 
period, all studies we found with RCTs 
designs are still ongoing.This review 
shows CP therapy gave an improvement 
of overall clinical condition, radiological 
findings, improvement of pulmonary 
function, and negative PCR results after 
transfusion. This passive immunity 
helps to neutralize the virus as well as 
improving cytotoxicity and phagocytosis 
by harnessing the innate immunity.16 
Acute Respiratory distress syndrome 
condition was resolved in the majority 
of all cases probably due to the works of 
CP in subsiding the cytokine storm. This 
response might help to reduce mortality 
as there was no death reported from 
our included studies. This finding was 
similar to studies in SARS patients in 
2005 (0% vs 24% mortality in patients 
without CP therapy, p<0.05)17 and H1N1 
patients in 2009 (Odds Ratio 0.20 [95% 
CI: 0.06–0·69], p=0.01).18
There were various initiation days 
of the transfusion and dose given in our 
review. The total dosage of CP therapy 
varied between studies, but the majority 
of the cases used 200 mL as a preferred 
dose and were repeated into several 
transfusion cycles.  The dose of CP and 
the titer of antibodies either total IgG or 
viral neutralizing antibody given varied 
from the included studies as the standard 
of how this transfusion had to be given 
is still unavailable. Clinicians might 
have used the recommended dose of 
convalescent therapy based on the study 
of SARS patients. This study showed 
promising results in decreasing the 
mortality and length of hospitalization.17 
This study utilized 5 mL/kg of plasma 
with plasma titer of more than equal 
1:160 and would result in 200-400 mL of 
plasma given. 
The achievement of negative viral 
load required various duration from 
day one to 26 with median of two days, 
as presented in TABLE 5. The longer 
duration to achieve negative viral load 
inCase 1 may be explained by the fact of 
the later use of transfusion in the first 
case i.e after 22 days from the onset of 
symptoms, although for Case 2 it was 
admnistered only after seven days from 
the onset. In the study from Shen et al,8 
the convalescent plasma transfusion 
was administered 10 to 22 days after 
admission. Therefore whether a 
different timing of administration would 
have been associated with different 
outcomes cannot be determined so far. 
Furthermore, because the transfusion 
were not in the early phase of the disease, 
it is difficult to determine clearly that 
the decrease in the viral load shown in 
both cases is due to convalescent plasma 
or natural pathology of COVID-19. The 
first two cases in this table presented 
severe ARDS and the viral loads were in 
increasing trend at the time of plasma 
infusion regardless of the date of disease 
onset.12
This review shows only one case 
of side effect after transfusion due 
to allergic reaction. The side effects 
of CP transfusion are similar to any 
blood product transfusions, such as 
anaphylactic shock, transfusion-related 
lung injury (TRALI), and transfusion-
associated circulatory overload (TACO).19 
Theoretically, CP transfusion may induce 
antibody-dependent enhancement of 
infection (ADE) phenomenon wherein 
normal mechanisms of antigen-antibody 
complex clearance fail, and instead 
provide an alternate route for host cell 
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infection and eventually worsen the 
disease. 19 This theoretical risk can be 
minimized by the measurement of viral 
neutralizing antibody titer in the plasma 
before given to the patient.
Our review only consisted of few 
patients with less severe COVID-19 
disease, so we could not conclude if there 
were different responses based on the 
disease severity. However, we found that 
patients with severe comorbid needed 
more doses of the CP transfusion, as seen 
in one patient in the study by Zhang et 
al.15
The limitation of this review is that 
we only included found case series 
studies, and the patients' characteristics 
were heterogeneous. The patients in 
the included studies had different 
ages, comorbid conditions, and already 
received different medication (antivirals, 
antibiotics, and corticosteroids) before, 
during, and after the transfusion. 
Therefore, the true effect of CP therapy 
was unknown due to the influence of 
other therapies. We could not conduct 
pooled analysis and make comparisons 
with other interventions because of the 
study design of available studies (case 
series). Furthermore, our study is a rapid 
review, so we made limitations during 
the literature searching.
We suggest a clinical trial of CP 
therapy in COVID-19 patients with 
standardized methods and dosage of 
the plasma. So, the response after the 
therapy can be seen based on different 
clinical characteristics of the patients, 
such as sex, age, and severity of the 
disease. 
CONCLUSION
Convalescent plasma therapy in 
COVID-19 patients shows promising 
results as it improved clinical symptoms, 
laboratory and imaging parameters. 
It is also well-tolerated based on our 
included studies. Although it is too early 
to be confident that all improvements are 
merely because of the transfusion due 
to diverse baseline clinical conditions, 
other treatments received, comorbidities 
and different day of transfusion after 
admission. Further clinical trials with 
expanded number of patients and 
comparable group of patient with similar 
characteristics and the same standard 
treatments are necessary to conclude a 
definitive statement about the efficacy 
of CP therapy. Although such idea will be 
quite challenging to be done in the era of 
an epidemic. 
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Search Strategies until April 20th 2020
MEDLINE via OVID EMBASE via OVID CENTRAL
Coronavirus Infections/ 
(5392)
Coronavirus Infections/ 
(1581)
COVID-19 (46)
Coronavirus/ (2003) Coronavirus/ (6747) SARS-COV-2 infection (2)
covid$19.tw. (4802) covid$19.tw. (4774) Coronavirus (144)
2019 coronavirus.tw. (52) 2019 coronavirus.tw. (43) 1 OR 2 OR 3 (156)
coronavirus disease 2019.
tw. (797)
coronavirus disease 2019.tw. 
(543)
“convalescent plasma”(40)
sars-cov-2.tw. (1163) sars-cov-2.tw. (790) “immunoglobulin therapy” (7397)
1 or 2 or 3 or 4 or 5 or 6 
(10804)
1 or 2 or 3 or 4 or 5 or 6 
(12771)
5 OR 6 (7428)
convalescen* plasma.tw. 
(159)
convalescen* plasma.tw. 
(182)
4 AND 7 (6)
convalescen* therapy.tw. 
(8)
convalescen* therapy.tw. (8)
8 or 9 (167) 8 or 9 (190)
7 and 10 (33) 7 and 10 (16)
Appendix 2
PRISMA Checklist
Section/topic # Checklist item Reported on Page
TITLE 
Title 1 Identify the report as a systematic 
review, meta-analysis, or both. 
1
ABSTRACT 
Structured 
summary 
2 Provide a structured summary 
including, as applicable: background; 
objectives; data sources; study 
eligibility criteria, participants, and 
interventions; study appraisal and 
synthesis methods; results; limitations; 
conclusions and implications of 
key findings; systematic review 
registration number. 
1, 2
INTRODUCTION 
Rationale 3 Describe the rationale for the review 
in the context of what is already 
known. 
3
Objectives 4 Provide an explicit statement 
of questions being addressed 
with reference to participants, 
interventions, comparisons, outcomes, 
and study design (PICOS). 
3
METHODS 
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Protocol and 
registration 
5 Indicate if a review protocol exists, 
if and where it can be accessed (e.g., 
Web address), and, if available, 
provide registration information 
including registration number. 
N/A
Eligibility 
criteria 
6 Specify study characteristics (e.g., 
PICOS, length of follow-up) and report 
characteristics (e.g., years considered, 
language, publication status) used as 
criteria for eligibility, giving rationale. 
4
Information 
sources 
7 Describe all information sources in the 
search and date last searched. 
4
Search 8 Present full electronic search strategy 
for at least one database, including 
any limits used, such that it could be 
repeated. 
4
Study selection 9 State the process for selecting studies 
(i.e., screening, eligibility, included in 
systematic review, and, if applicable, 
included in the meta-analysis). 
4
Data collection 
process 
10 Describe method of data extraction 
from reports (e.g., piloted forms, 
independently, in duplicate) and 
any processes for obtaining and 
confirming data from investigators. 
4
Data items 11 List and define all variables for which 
data were sought (e.g., PICOS, funding 
sources) and any assumptions and 
simplifications made. 
4
Risk of bias 
in individual 
studies 
12 Describe methods used for assessing 
risk of bias of individual studies 
(including specification of whether 
this was done at the study or outcome 
level), and how this information is to 
be used in any data synthesis. 
5
Summary 
measures 
13 State the principal summary measures 
(e.g., risk ratio, difference in means). 
5
Synthesis of 
results 
14 Describe the methods of handling 
data and combining results of studies, 
if done, including measures of 
consistency (e.g., I2) for each meta-
analysis. 
5
Risk of bias 
across studies 
15 Specify any assessment of risk of 
bias that may affect the cumulative 
evidence (e.g., publication bias, 
selective reporting within studies). 
N/A
Additional 
analyses 
16 Describe methods of additional 
analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, 
indicating which were pre-specified. 
N/A
RESULTS 
Study selection 17 Give numbers of studies screened, 
assessed for eligibility, and included in 
the review, with reasons for exclusions 
at each stage, ideally with a flow 
diagram. 
6, Figure 1
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Study 
characteristics 
18 For each study, present characteristics 
for which data were extracted (e.g., 
study size, PICOS, follow-up period) 
and provide the citations. 
6, Table 1
Risk of bias 
within studies 
19 Present data on risk of bias of each 
study and, if available, any outcome 
level assessment. 
6, Appendix 3
Results of 
individual 
studies 
20 For all outcomes considered (benefits 
or harms), present, for each study: 
(a) simple summary data for each 
intervention group (b) effect estimates 
and confidence intervals, ideally with 
a forest plot. 
7-11
Synthesis of 
results 
21 Present results of each meta-analysis 
done, including confidence intervals 
and measures of consistency. 
N/A
Risk of bias 
across studies 
22 Present results of any assessment of 
risk of bias across studies (see Item 
15). 
N/A
Additional 
analysis 
23 Give results of additional analyses, 
if done (e.g., sensitivity or subgroup 
analyses, meta-regression [see Item 
16]). 
N/A
DISCUSSION 
Summary of 
evidence 
24 Summarize the main findings 
including the strength of evidence 
for each main outcome; consider 
their relevance to key groups (e.g., 
healthcare providers, users, and policy 
makers). 
11-13
Limitations 25 Discuss limitations at study and 
outcome level (e.g., risk of bias), and at 
review-level (e.g., incomplete retrieval 
of identified research, reporting bias). 
13
Conclusions 26 Provide a general interpretation of 
the results in the context of other 
evidence, and implications for future 
research. 
13
Appendix 3
Summary of Critical Appraisal of Included Studies Using The Joanna Briggs Institute 
Critical Appraisal Tools for Case Series
Authors
Criteria 
for 
Inclusion
Measurement 
of Condition
Identification 
of Patients’ 
Condition
Consecutive 
Inclusion of 
Participants
Complete 
Inclusion of 
Participants
Reporting of 
Participants’ 
Demographic
Reporting 
of Clinical 
Information
Clear Report 
of Outcomes 
or Follow-ups
Reporting of 
Sites or Clinics 
Demographics
Appropriate 
Statistical 
Analysis
Ahn, 2020 Unclear Yes Yes Unclear Unclear Yes Yes Yes Unclear Not Applicable
Duan, 2020 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Shen, 2020 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Ye, 2020 Unclear Yes Yes Unclear Unclear Yes Yes Yes Yes Not Applicable
Zhang, 2020 Unclear Yes Yes Unclear Unclear Yes Yes Yes Unclear Not Applicable
